Abstract
The field of pharmacogenomics aims to predict which drugs will be most effective and safe for a particular individual based on their genome sequence or expression profile, thereby allowing personalized treatment. The bulk of pharmacogenomic research has focused on the role of single nucleotide polymorphisms, copy number variations or differences in gene expression levels of drug metabolizing or transporting genes and drug targets. In this review paper, we focus instead on microRNAs (miRNAs): small noncoding RNAs, prevalent in metazoans, that negatively regulate gene expression in many cellular processes. We discuss how miRNAs, by regulating the expression of pharmacogenomic-related genes, can play a pivotal role in drug efficacy and toxicity and have potential clinical implications for personalized medicine.
| Original language | English |
|---|---|
| Pages (from-to) | 412-423 |
| Number of pages | 12 |
| Journal | Trends in Molecular Medicine |
| Volume | 17 |
| Issue number | 8 |
| DOIs | |
| State | Published - Aug 2011 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Molecular Biology
Fingerprint
Dive into the research topics of 'MicroRNA pharmacogenomics: Post-transcriptional regulation of drug response'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver